Compare AA & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AA | GH |
|---|---|---|
| Founded | 1888 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aluminum | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7B | 13.3B |
| IPO Year | 2016 | 2018 |
| Metric | AA | GH |
|---|---|---|
| Price | $59.06 | $88.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 20 |
| Target Price | $51.50 | ★ $117.80 |
| AVG Volume (30 Days) | ★ 5.7M | 1.6M |
| Earning Date | 04-16-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.62% | N/A |
| EPS Growth | ★ 1580.77 | 6.74 |
| EPS | ★ 4.37 | N/A |
| Revenue | ★ $12,831,000,000.00 | $982,021,000.00 |
| Revenue This Year | $10.24 | $33.40 |
| Revenue Next Year | $1.46 | $28.55 |
| P/E Ratio | $14.73 | ★ N/A |
| Revenue Growth | 7.87 | ★ 32.88 |
| 52 Week Low | $21.53 | $36.36 |
| 52 Week High | $68.40 | $120.74 |
| Indicator | AA | GH |
|---|---|---|
| Relative Strength Index (RSI) | 43.62 | 40.38 |
| Support Level | $55.70 | $82.26 |
| Resistance Level | $66.71 | $103.16 |
| Average True Range (ATR) | 3.90 | 3.84 |
| MACD | -0.23 | 0.13 |
| Stochastic Oscillator | 23.89 | 48.18 |
Alcoa is a vertically integrated aluminum company whose operations include bauxite mining, alumina refining, and manufacturing primary aluminum. It is one of the world's largest bauxite miners and alumina refiners by production volume, but sits outside the top-10 aluminum producers, a list dominated by Chinese companies. Profits are closely tied to prevailing commodity prices along the aluminum supply chain.Alcoa was the first mass producer of aluminum, launching the world-changing Hall-Heroult smelting process in the 1880s, making aluminum affordable. It listed as a public company in 1925. In 2016, Alcoa spun off its automotive and aerospace metal parts segment to focus on mining, smelting, and refining. It bought the 40% unowned balance of AWAC in mid-2024.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.